Review
Clinical Neurology
Kyu Hwan Shim, Min Ju Kang, Young Chul Youn, Seong Soo A. An, SangYun Kim
Summary: The study reviews and summarizes the physiological and pathophysiological functions, structures, and genetics of alpha-syn in Alzheimer's disease (AD). Numerous associations of alpha-syn with A beta and tau suggest its significance as a partner in the pathological roles of AD. Understanding the involvement of alpha-syn in the pathology of A beta and tau could help address unresolved issues of AD. Specifically, the current status of CSF alpha-syn in AD recommends it as an additional biomarker in AD diagnosis.
ALZHEIMERS RESEARCH & THERAPY
(2022)
Article
Clinical Neurology
Andrea Pilotto, Matilde Bongianni, Clara Tirloni, Alice Galli, Alessandro Padovani, Gianluigi Zanusso
Summary: This study aimed to evaluate the prevalence and clinical features associated with cerebrospinal fluid (CSF) aSyn detected by seed amplification assay (SAA) in Alzheimer's disease (AD). The findings showed that about 45% of AD patients have concomitant CSF aSyn pathology in the early stages, which may affect the clinical presentation of the disease.
ALZHEIMERS & DEMENTIA
(2023)
Article
Clinical Neurology
Fardin Nabizadeh, Kasra Pirahesh, Parya Valizadeh
Summary: The study found that the changes in CSF alpha-syn, t-tau, and p-tau were not significant enough to distinguish PD patients with and without RBD. However, CSF A beta 1-42 decreased in the short term and showed a significant difference after a while in PD patients with and without RBD.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Steffen Halbgebauer, Patrick Oeckl, Petra Steinacker, Deniz Yilmazer-Hanke, Sarah Anderl-Straub, Christine von Arnim, Lutz Froelich, Luis Aragao Gomes, Lucrezia Hausner, Andre Huss, Holger Jahn, Jochen Weishaupt, Albert C. Ludolph, Dietmar R. Thal, Markus Otto
Summary: A novel ELISA was established to evaluate beta-synuclein as a potential marker for Alzheimer's disease. The study found increased levels of beta-synuclein in the CSF of some patients, supporting its potential use as a marker of synaptic degeneration. Furthermore, beta-synuclein was localized in glutamatergic synapses, with its expression reduced in AD patients' brain tissue.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2021)
Article
Cell Biology
Katelyn Mroczek, Sanjanie Fernando, Paul R. Fisher, Sarah J. Annesley
Summary: Tau and alpha-synuclein exhibit different but overlapping patterns of intracellular localization, exerting distinct but overlapping patterns of cytotoxic effects. They may interact physically in the cell cortex, affecting some phenotypes.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Clinical Neurology
Anniina Snellman, Juan Lantero-Rodriguez, Andreja Emersic, Agathe Vrillon, Thomas K. Karikari, Nicholas J. Ashton, Milica Gregoric Kramberger, Sasa Cucnik, Claire Paquet, Uros Rot, Henrik Zetterberg, Kaj Blennow
Summary: The study develops new N-terminal-directed CSF total tau assays, which show increased levels ahead of standard t-tau in the Alzheimer's disease continuum, higher levels in patients with CJD or acute neurological diseases, and better potential as Alzheimer's disease blood biomarkers compared to Quanterix total tau.
Article
Biochemistry & Molecular Biology
Ioanna Tsantzali, Aikaterini Foska, Eleni Sideri, Evdokia Routsi, Effrosyni Tsomaka, Dimitrios K. Kitsos, Christina Zompola, Anastasios Bonakis, Sotirios Giannopoulos, Konstantinos I. Voumvourakis, Georgios Tsivgoulis, George P. Paraskevas
Summary: CSF biomarkers are the gold standard for AD diagnosis, but plasma biomarkers may provide an alternative method with comparable accuracy and the advantage of avoiding lumbar puncture.
Article
Clinical Neurology
William Charles Kreisl, Patrick J. Lao, Aubrey Johnson, Zeljko Tomljanovic, Julia Klein, Krista Polly, Benjamin Maas, Krystal K. Laing, Anthony G. Chesebro, Kay Igwe, Qolamreza R. Razlighi, Lawrence S. Honig, Xinyu Yan, Seonjoo Lee, Akiva Mintz, Jose A. Luchsinger, Yaakov Stern, D. P. Devanand, Adam M. Brickman
Summary: F-18-MK-6240 showed good correlation with CSF tau and p-tau levels, as well as age, cognition, and amyloid-based AD biomarkers. The study also found that F-18-MK-6240 binding patterns were associated with specific cognitive impairments in amyloid-positive participants, reflecting the progression of AD pathology.
ALZHEIMERS & DEMENTIA
(2022)
Review
Biochemistry & Molecular Biology
Sarah Holper, Rosie Watson, Nawaf Yassi
Summary: The advances in tau detection have revolutionized the diagnosis of neurodegenerative diseases, offering improved diagnostic accuracy and potential as a predictor of clinical progression and drug therapy response.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Clinical Neurology
Juan Lantero-Rodriguez, Cecile Tissot, Anniina Snellman, Stijn Servaes, Andrea L. L. Benedet, Nesrine Rahmouni, Laia Montoliu-Gaya, Joseph Therriault, Wagner S. S. Brum, Jenna Stevenson, Firoza Z. Z. Lussier, Gleb Bezgin, Arthur C. C. Macedo, Mira Chamoun, Sulantha S. S. Mathotaarachi, Tharick A. A. Pascoal, Nicholas J. J. Ashton, Henrik Zetterberg, Pedro Rosa Neto, Kaj Blennow
Summary: This study evaluated the concentrations of N-terminal tau fragments (NTA-tau) in cerebrospinal fluid (CSF) and plasma using a novel immunoassay (NTA) in the TRIAD cohort. The results showed that CSF and plasma NTA-tau concentrations were specifically increased in cognitively impaired A beta-positive groups and displayed stronger correlations with tau positron emission tomography (PET) than with amyloid PET and magnetic resonance imaging (MRI). NTA-tau has potential as a tau tangle biomarker in clinical settings and trials.
ALZHEIMERS & DEMENTIA
(2023)
Article
Neurosciences
Brian D. Hitt, Jaime Vaquer-Alicea, Victor A. Manon, Joshua D. Beaver, Omar M. Kashmer, Jan N. Garcia, Marc I. Diamond
Summary: Tau protein forms self-replicating assemblies that may contribute to the progression of Alzheimer's disease and related conditions. Improved biosensor cell lines, such as the v2H cells, have been developed to detect tau seeding activity in cerebrospinal fluid with greater sensitivity. However, the findings of tau seeding in AD patients' CSF have not been widely replicated.
ACTA NEUROPATHOLOGICA COMMUNICATIONS
(2021)
Review
Biochemistry & Molecular Biology
Eun Hae Kwon, Sabrina Tennagels, Ralf Gold, Klaus Gerwert, Leon Beyer, Lars Toenges
Summary: This paper emphasizes the importance of reliable objective markers for identifying individuals at risk of Parkinson's disease. Advances in biomarker discovery, particularly in the cerebrospinal fluid (CSF), have provided promising preliminary results. Potential biomarkers include alpha-synuclein species, markers of amyloid and tau pathology, neurofilament light chain, lysosomal enzymes, and markers of neuroinflammation. Metabolomics approaches have also offered insights into novel biological pathways. Genetic forms of PD can help identify subgroups suitable for targeted treatments. Further validation studies are needed to determine the most valuable CSF biomarkers or combinations for clinical and research purposes.
Article
Multidisciplinary Sciences
Eleanor Sinclair, Drupad K. Trivedi, Depanjan Sarkar, Caitlin Walton-Doyle, Joy Milne, Tilo Kunath, Anouk M. Rijs, Rob M. A. de Bie, Royston Goodacre, Monty Silverdale, Perdita Barran
Summary: This study used metabolomics profiling to identify changes in lipids in the sebum of PD patients, with alterations related to the carnitine shuttle, sphingolipid metabolism, arachidonic acid metabolism, and fatty acid biosynthesis. The findings suggest sebum can be a potential source for identifying biomarkers for PD.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Deepthy Kavungal, Pedro Magalhaes, Senthil T. Kumar, Rajasekhar Kolla, Hilal A. Lashuel, Hatice Altug
Summary: We have developed an immunoassay-coupled nanoplasmonic infrared metasurface sensor that can detect proteins linked to neurodegenerative disorders (NDDs) and differentiate their distinct structural species. The sensor is augmented with an artificial neural network for quantitative prediction of protein aggregates. It can retrieve time-resolved absorbance fingerprints in complex biomatrices and can multiplex for simultaneous monitoring of multiple pathology-associated biomarkers. Therefore, our sensor shows promise for clinical diagnosis, disease monitoring, and evaluation of novel therapies for NDDs.
Article
Neurosciences
Soyeon Kim, Kiwon Kim, Kwangsik Nho, Woojae Myung, Hong-Hee Won
Summary: The study found a causal association between CSF biomarkers and the risk of LOAD, suggesting that the etiology of LOAD involves pathways of A beta and tau proteins. Further MR studies using large-scale data are needed to elucidate the pathophysiology of LOAD.
JOURNAL OF ALZHEIMERS DISEASE
(2021)
Article
Psychiatry
Maurits Johansson, Erik Stomrud, Philip S. Insel, Antoine Leuzy, Per Marten Johansson, Ruben Smith, Zahinoor Ismail, Shorena Janelidze, Sebastian Palmqvist, Danielle van Westen, Niklas Mattsson-Carlgren, Oskar Hansson
Summary: The study revealed that in early-stage Alzheimer's disease, mild behavioral impairment is associated with tau pathology independently of memory deficits. This indicates that mild behavioral impairment is an important early clinical manifestation related to tau pathology in Alzheimer's disease.
TRANSLATIONAL PSYCHIATRY
(2021)
Article
Clinical Neurology
Oskar Hansson, Nicholas Cullen, Henrik Zetterberg, Kaj Blennow, Niklas Mattsson-Carlgren
Summary: The study found that high plasma tau levels were associated with hypometabolism and cortical atrophy, and these associations were observed only in Aβ-positive participants. Plasma phosphorylated tau may help identify and track processes linked to neurodegeneration in Alzheimer's disease.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2021)
Article
Clinical Neurology
Shorena Janelidze, David Berron, Ruben Smith, Olof Strandberg, Nicholas K. Proctor, Jeffrey L. Dage, Erik Stomrud, Sebastian Palmqvist, Niklas Mattsson-Carlgren, Oskar Hansson
Summary: This study highlights the potential of plasma P-tau217 as an early biomarker for Alzheimer's disease, showing elevated levels before tau-PET detected insoluble tau aggregates. Modeling suggests that changes in plasma and CSF P-tau217 precede tau-PET signals, indicating its usefulness in detecting early AD brain pathology.
Article
Clinical Neurology
David Berron, Jacob W. Vogel, Philip S. Insel, Joana B. Pereira, Long Xie, Laura E. M. Wisse, Paul A. Yushkevich, Sebastian Palmqvist, Niklas Mattsson-Carlgren, Erik Stomrud, Ruben Smith, Olof Strandberg, Oskar Hansson
Summary: The study reveals the progression of tau pathology across subregions within the medial temporal lobe and its specific association with memory performance at different disease stages. In cognitively unimpaired individuals, increased tau load is linked to local atrophy and memory performance, while in mild cognitive impairment patients, the association between hippocampal tau load and memory performance is partially mediated by posterior hippocampal atrophy.
Review
Medicine, Research & Experimental
Antoine Leuzy, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Shorena Janelidze, Jeffrey L. Dage, Oskar Hansson
Summary: Blood-based biomarkers are playing an increasing role in the diagnosis and research of neurodegenerative disorders like Alzheimer's disease. Biomarkers such as plasma P-tau and NfL show promising potential for detection and monitoring of these diseases.
EMBO MOLECULAR MEDICINE
(2022)
Article
Neurosciences
Erik Blennow Nordstrom, Gisela Lilja, Susann Ullen, Kaj Blennow, Hans Friberg, Christian Hassager, Jesper Kjaergaard, Niklas Mattsson-Carlgren, Marion Moseby-Knappe, Niklas Nielsen, Susanna Vestberg, Henrik Zetterberg, Tobias Cronberg
Summary: This study explored the associations between different methods of assessing long-term neurocognitive outcome after out-of-hospital cardiac arrest and early hypoxic-ischemic brain injury assessed by a biomarker. The results showed that serum neurofilament light (NFL) was associated with all outcome instruments, but the association with patient-reported measures was weaker. The clinician-reported Cerebral Performance Category (CPC) was mostly related to hypoxic-ischemic brain injury, but had a ceiling effect.
Article
Clinical Neurology
Atul Kumar, Shorena Janelidze, Erik Stomrud, Sebastian Palmqvist, Oskar Hansson, Niklas Mattsson-Carlgren
Summary: This study investigated the associations between genetic risk factors for Alzheimer's disease (AD) and biomarkers in cerebrospinal fluid (CSF). The results showed that the genetic risk scores were associated with higher levels of soluble phosphorylated tau, and these associations were partly mediated by beta-amyloid pathology. The study identified Aβ-dependent and Aβ-independent subsets of the genetic risk scores. The findings have implications for the development of anti-tau drugs.
Article
Clinical Neurology
Colin Groot, Ruben Smith, Erik Stomrud, Alexa Pichet Binette, Antoine Leuzy, Anika Wuestefeld, Laura E. M. Wisse, Sebastian Palmqvist, Niklas Mattsson-Carlgren, Shorena Janelidze, Olof Strandberg, Rik Ossenkoppele, Oskar Hansson
Summary: Among amyloid-positive individuals, tau discordance predicts increased rates of tau accumulation on PET, but not increased cognitive decline or cortical thinning. Individuals with this biomarker profile may be an interesting target group for intervention in early Alzheimer's disease.
Editorial Material
Clinical Neurology
Niklas Mattsson-Carlgren, Sebastian Palmqvist
Article
Medicine, Research & Experimental
Gemma Salvado, Rik Ossenkoppele, Nicholas J. Ashton, Thomas G. Beach, Geidy E. Serrano, Eric M. Reiman, Henrik Zetterberg, Niklas Mattsson-Carlgren, Shorena Janelidze, Kaj Blennow, Oskar Hansson
Summary: Several promising plasma biomarkers for Alzheimer's disease have been developed, but their neuropathological correlates are not fully understood. This study investigates the associations between multiple plasma biomarkers and amyloid and tau neuropathological measures. The results suggest that plasma p-tau217 and A beta 42/40 might be an optimal combination for assessing Alzheimer's-related pathology.
EMBO MOLECULAR MEDICINE
(2023)
Article
Clinical Neurology
Eske Christiane Gertje, Shorena Janelidze, Danielle van Westen, Nicholas Cullen, Erik Stomrud, Sebastian Palmqvist, Oskar Hansson, Niklas Mattsson-Carlgren
Summary: There is an association between white matter lesions (WML) and CSF biomarkers of neuroinflammation in individuals without dementia. Especially, PlGF is associated with WML independent of Aβ status and cognitive impairment.
Article
Clinical Neurology
Elin Dybjer, Atul Kumar, Katarina Nagga, Gunnar Engstrom, Niklas Mattsson-Carlgren, Peter M. Nilsson, Olle Melander, Oskar Hansson
Summary: Dybjer et al. found that the polygenic risk of type 2 diabetes is associated with the risk of dementia, especially vascular dementia. However, further analysis did not support a causal relationship between type 2 diabetes and vascular dementia. It is still unclear whether the genetic risk markers for type 2 diabetes and dementia are the same or if there is a causal link between the two diseases.
BRAIN COMMUNICATIONS
(2023)
Article
Clinical Neurology
Erin M. Jonaitis, Shorena Janelidze, Karly A. Cody, Rebecca Langhough, Lianlian Du, Nathaniel A. Chin, Niklas Mattsson-Carlgren, Kirk J. Hogan, Bradley T. Christian, Tobey J. Betthauser, Oskar Hansson, Sterling C. Johnson
Summary: An accurate blood test for early detection of Alzheimer's disease is important for secondary prevention. In this study, plasma phosphorylated tau 217 (pTau(217)) was found to be strongly related to amyloid and tau PET markers, and could predict longitudinal cognitive performance.
BRAIN COMMUNICATIONS
(2023)
Article
Cell Biology
Joana B. Pereira, Shorena Janelidze, Olof Strandberg, Christopher D. Whelan, Henrik Zetterberg, Kaj Blennow, Sebastian Palmqvist, Erik Stomrud, Niklas Mattsson-Carlgren, Oskar Hansson
Summary: The study investigates the role of microglia in tau accumulation and cognitive decline, and identifies several cell markers associated with these processes. These findings have implications for the development of future therapeutic strategies for Alzheimer's disease.
Article
Clinical Neurology
Nicola Spotorno, Chloe Najac, Erik Stomrud, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Danielle van Westen, Itamar Ronen, Oskar Hansson
Summary: This study provides further evidence of the important role of astrocytes in the pathophysiology of Alzheimer's disease and investigates the relationship between APOE genotype, myo-inositol concentration, and Alzheimer's disease pathology. The results show an interaction between myo-inositol concentration and amyloid-beta deposition in APOE ε4 carriers.
BRAIN COMMUNICATIONS
(2022)